1887

Abstract

In this study the effects of 2-amino-phenoxazine-3-one (phenoxazine derivate, Phx-3) on () growth in human monocytic THP-1 cells as well as human epithelial HEp-2 cells were examined. Cells were infected with bacteria at an m.o.i. of 10 by centrifugation. After washing to remove any remaining bacteria, the cells were incubated with or without Phx-3 in the presence or absence of tryptophan for 72 h. The bacteria in cells were assessed by staining of chlamydial inclusions with FITC-labelled anti-chlamydial antibody, electron microscopic analysis, real-time RT-PCR specific for 16S rRNA and propagation on HEp-2 cells. Treatment with Phx-3 significantly inhibited growth of in THP-1 and HEp-2 cells. A decrease in the number of bacterial 16S rRNA transcripts was also confirmed in both cell lines by real-time RT-PCR. Electron microscopic studies revealed that treatment with Phx-3 induces bacterial destruction in most of the inclusion bodies in these cells. Addition of tryptophan to the culture slightly blocked the growth inhibition of by Phx-3. The reagents did not show any cytotoxicity to the cells at the concentrations used. The results suggest that Phx-3 inhibits replication in human monocytic cells as well as epithelial cells, partially depending on the tryptophan-metabolic pathway of host cells. Thus, Phx-3 might be a useful compound for controlling growth in cells and may be an alternative conventional therapy.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46090-0
2005-12-01
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/jmm/54/12/JM541205.html?itemId=/content/journal/jmm/10.1099/jmm.0.46090-0&mimeType=html&fmt=ahah

References

  1. Abe A., Yamane M., Tomoda A. 2001; Prevention of growth of human lung carcinoma cells and induction of apoptosis by a novel phenoxazinone, 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one. Anti-Cancer Drugs 12:377–383 [CrossRef]
    [Google Scholar]
  2. Airenne S., Surcel H. M., Sahney H., Laitinen K., Paavonen J., Saikku P., Laurila A. 1999; Chlamydia pneumoniae infection in human monocytes. Infect Immun 67:1445–1449
    [Google Scholar]
  3. Aldus M. B., Grayston J. T., Wang S. P., Foy H. M. 1992; Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966–1976. J Infect Dis 166:646–649 [CrossRef]
    [Google Scholar]
  4. Azuine M. A., Tokuda H., Takayasu J., Enjyo F., Mukainaka T., Konoshima T., Nishino H., Kapadia G. J. 2004; Cancer chemopreventive effect of phenothiazines and related tri-heterocyclic analogues in the 12-σ-tetradecanoylphorbol-13-acetate promoted Epstein-Barr virus early antigen activation and the mouse skin two-stage carcinogenesis models. Pharmacol Res 49:161–169 [CrossRef]
    [Google Scholar]
  5. Beatty W. L., Byrne G. I., Morrison R. P. 1993; Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro . Proc Natl Acad Sci U S A 90:3998–4002 [CrossRef]
    [Google Scholar]
  6. Berger M., Schroder B., Daeschlein G., Schneider W., Busjahn A., Buchwalow I., Luft F. C., Haller H. 2000; Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes. J Lab Clin Med 136:194–200 [CrossRef]
    [Google Scholar]
  7. Byrne G. I., Lehmann L. K., Landry G. J. 1986; Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun 53:347–351
    [Google Scholar]
  8. Esposito G., Blasi F., Allegra L. 8 other authors; 1999; Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction. Ann Vasc Surg 13:421–425 [CrossRef]
    [Google Scholar]
  9. Fan T., Lu H., Hu H., Shi L., McClarty G. A., Nance D., Greenberg A. H., Zhong G. 1998; Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med 187:487–496 [CrossRef]
    [Google Scholar]
  10. Gaydos C. A., Summersgill J. T., Sahney N. N., Ramirez J. A., Quinn T. C. 1996; Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 64:1614–1620
    [Google Scholar]
  11. Gerard H. C., Schumacher H. R., El-Gabalawy H., Goldbach-Mansky R., Hudson A. P. 2000; Chlamydia pneumoniae present in the human synovium are viable and metabolically active. Microb Pathog 29:17–24 [CrossRef]
    [Google Scholar]
  12. Gieffers J., Fullgraf H., Jahn J., Klinger M., Dalhoff K., Katus H. A., Solbach W., Maass M. 2001; Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 103:351–356 [CrossRef]
    [Google Scholar]
  13. Grayston J. T., Kuo C. C., Wang S. P., Altman J. 1986; A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 315:161–168 [CrossRef]
    [Google Scholar]
  14. Hahn D. L., Dodge R. W., Golubjatnikov R. 1991; Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 266:225–230 [CrossRef]
    [Google Scholar]
  15. Haranaga S., Ikejima H., Yamaguchi H., Friedman H., Yamamoto Y. 2002; Analysis of Chlamydia pneumoniae growth in cells by reverse transcription-PCR targeted to bacterial gene transcripts. Clin Diagn Lab Immunol 9:313–319
    [Google Scholar]
  16. Holmes S. C., Gait M. J. 2003; The synthesis of 2′-O-methyl G-clamp containing oligonucleotides and their inhibition of the HIV-1 Tat-TAR interaction. Nucleosides Nucleotides Nucleic Acids 22:1259–1262 [CrossRef]
    [Google Scholar]
  17. Ishida R., Yamanaka S., Kawai H., Ito H., Iwai M., Nishizawa M., Hamatake M., Tomoda A. 1996; Antitumor activity of 2-amino-4,4 alpha-dihydro-4 alpha, 7-dimethyl-3H-phenoxazine-3-one, a novel phenoxazine derivative produced by the reaction of 2-amino-5-methylphenol with bovine hemolysate. Anticancer Drugs 7:591–595 [CrossRef]
    [Google Scholar]
  18. Iwata A., Yamaguchi T., Sato K., Izumi R., Tomoda A. 2003; Antiviral activity of 2-amino-4,4α-dihydro-4α-7-dimethyl-3H-phenoxazine-3-one on poliovirus. Tohoku J Exp Med 200:161–165 [CrossRef]
    [Google Scholar]
  19. Lin T. M., Campbell L. A., Rosenfeld M. E., Kuo C. C. 2000; Monocyte-endothelial cell coculture enhances infection of endothelial cells with Chlamydia pneumoniae . J Infect Dis 181:1096–1100 [CrossRef]
    [Google Scholar]
  20. Moazed T. C., Kuo C. C., Grayston J. T., Campbell L. A. 1998; Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 177:1322–1325 [CrossRef]
    [Google Scholar]
  21. Ossewaarde J. M., de Vries A., Bestebroer T., Angulo A. F. 1996; Application of a Mycoplasma group-specific PCR for monitoring decontamination of Mycoplasma -infected Chlamydia sp.strains. Appl Environ Microbiol 62:328–331
    [Google Scholar]
  22. Roblin P. M., Dumornay W., Hammerschlag M. R. 1992; Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae . J Clin Microbiol 30:1968–1971
    [Google Scholar]
  23. Rottenberg M., Gigliotti-Rothfuchs A., Wigzell H. 2002; The role of IFN-γ in the outcome of chlamydial infection. Curr Opin Immunol 14:444–451 [CrossRef]
    [Google Scholar]
  24. Saikku P. 1992; The epidemiology and significance of Chlamydia pneumoniae . J Infect 25 (Suppl. 1):27–34
    [Google Scholar]
  25. Saikku P., Wang S. P., Kleemola M., Brander E., Rusanen E., Grayston J. T. 1985; An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci . J Infect Dis 151:832–839 [CrossRef]
    [Google Scholar]
  26. Shaw E. I., Dooley C. A., Fischer E. R., Scidmore M. A., Fields K. A., Hackstadt T. 2000; Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle. Mol Microbiol 37:913–925 [CrossRef]
    [Google Scholar]
  27. Shemer Y., Sarov I. 1985; Inhibition of growth of Chlamydia trachomatis by human gamma interferon. Infect Immun 48:592–596
    [Google Scholar]
  28. Summersgill J. T., Sahney N. N., Gaydos C. A., Quinn T. C., Ramirez J. A. 1995; Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha. Infect Immun 63:2801–2803
    [Google Scholar]
  29. Tomoda A., Yamaguchi J., Kojima H., Amemiya H., Yoneyama Y. 1986; Mechanism of σ-aminohenol metabolism in human erythrocytes. FEBS Lett 196:44–48 [CrossRef]
    [Google Scholar]
  30. Tomoda A., Hamashima H., Arisawa M., Kikuchi T., Tezuka Y., Koshimura S. 1992; Phenoxazine synthesis by human hemoglobin. Biochem Biophys Acta 1117:306–314 [CrossRef]
    [Google Scholar]
  31. Vasilescu A., Andreescu S., Bala C., Litescu S. C., Noguer T., Marty J. L. 2003; Screen-printed electrodes with electropolymerized Meldola Blue as versatile detectors in biosensors. Biosens Bioelectron 18:781–790 [CrossRef]
    [Google Scholar]
  32. von Hertzen L., Leinonen M., Surcel H. M., Karjalainen J., Saikku P. 1995; Measurement of sputum antibodies in the diagnosis of acute and chronic respiratory infections associated with Chlamydia pneumoniae . Clin Diagn Lab Immunol 2:454–457
    [Google Scholar]
  33. Yamaguchi H., Haranaga S., Friedman H., Moor J. A., Muffly K. E., Yamamoto Y. 2002; A Chlamydia pneumoniae infection model using established human lymphocyte cell lines. FEMS Microbiol Lett 216:229–234 [CrossRef]
    [Google Scholar]
  34. Yamaguchi H., Friedman H., Yamamoto M., Yasuda K., Yamamoto Y. 2003; Chlamydia pneumoniae resists antibiotics in lymphocytes. Antimicrob Agents Chemother 47:1972–1975 [CrossRef]
    [Google Scholar]
  35. Yamaguchi H., Yamada M., Uruma T., Kanamori M., Goto H., Yamamoto Y., Kamiya S. 2004; Prevalence of viable Chlamydia pneumoniae in peripheral blood mononuclear cells of healthy blood donors. Transfusion 44:1072–1078 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46090-0
Loading
/content/journal/jmm/10.1099/jmm.0.46090-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error